External experts, including key opinion leaders (KOLs) and subject matter experts (SMEs), play a crucial role in pharmaceutical innovation and scientific communication. Their insights drive medicine development, regulatory approval, and pre- and post-approval strategies. The collaboration between pharmaceutical companies and medical societies is vital for advancing clinical knowledge, updating guidelines, and therapeutic advancements. Ethical considerations, transparency, and compliance with industry regulations (EFPIA, PhRMA, Sunshine Act) govern these interactions. Technology has enhanced engagement through virtual advisory boards, Artificial Intelligence (AI)-driven expert mapping, and real-time collaboration tools. Companies must ensure that expert engagement strategies align with scientific integrity and regulatory frameworks to maintain credibility and trust.